These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29252193)

  • 1. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.
    Ragia G; Karantza IM; Kelli-Kota E; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
    Drug Metab Pers Ther; 2017 Dec; 32(4):183-190. PubMed ID: 29252193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
    Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
    Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
    Ragia G; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
    Pharmacogenomics; 2017 Jan; 18(1):23-34. PubMed ID: 27967328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Sai Chandran BV; Balachander J; Adithan C
    Eur J Clin Pharmacol; 2015 Feb; 71(2):173-81. PubMed ID: 25519826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
    Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
    Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.
    Pérez-Andreu V; Roldán V; López-Fernández MF; Antón AI; Alberca I; Corral J; Montes R; García-Barberá N; Ferrando F; Vicente V; González-Conejero R
    J Thromb Haemost; 2010 May; 8(5):1012-7. PubMed ID: 20149073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
    Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
    Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
    Jiménez-Varo E; Cañadas-Garre M; Gutiérrez-Pimentel MJ; Calleja-Hernández MA
    Pharmacogenet Genomics; 2014 Oct; 24(10):501-13. PubMed ID: 25089947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements.
    Saraeva RB; Paskaleva ID; Doncheva E; Eap CB; Ganev VS
    J Clin Pharm Ther; 2007 Dec; 32(6):641-9. PubMed ID: 18021343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
    Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acenocoumarol Pharmacogenetic Dosing Algorithms and Their Application in Two Bulgarian Patients with Low Anticoagulant Requirements.
    Dimitrova-Karamfilova A; Tzveova R; Chilingirova N; Goranova T; Nachev G; Mitev V; Kaneva R
    Biochem Genet; 2015 Dec; 53(11-12):334-50. PubMed ID: 26377995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
    Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
    J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.